|Over a week ago|
Wedbush starts Curaleaf with Outperform, expects share gains » 16:1512/0112/01/22
Wedbush analyst Gerald…
Wedbush analyst Gerald Pascarelli initiated coverage of Curaleaf with an Outperform rating and $8.50 price target. Curaleaf is the largest U.S. cannabis operator and should be well positioned to realize incremental benefits from the rollout of adult use sales in new states in addition to benefiting from better performance in its many legacy markets, Pascarelli tells investors in a research note. He expects the company to be a net share gainer and outpace the broad industry.
Curaleaf initiated with an Outperform at Wedbush » 16:0412/0112/01/22
Wedbush analyst Gerald…
Wedbush analyst Gerald Pascarelli initiated coverage of Curaleaf with an Outperform rating and $8.50 price target.
Rising High: Exclusive talk with cannabis REIT NewLake Capital » 09:4611/2511/25/22
NLCP, AYRWF, CURLF, ACB, CVSI, CTST, CGC, CRON, CANN, GDNSF, GTBIF, IGC, TLRY, TCNNF, ZYNE, ATAI, CMPS, RLMD
In this edition of…
Curaleaf opens two new Florida dispensaries » 08:1411/2211/22/22
Curaleaf Holdings announced the opening of two new Florida dispensaries, Orlando International Drive and Miami South Beach. The new locations are Curaleaf's 53rd and 54th locations to open in the Sunshine State and 144th nationwide.
Curaleaf announces strategic national rebrand of Grassroots » 08:1011/1411/14/22
Curaleaf Holdings announced the national rebrand of its Grassroots premium cannabis flower brand, and shared details on the brand's previously announced expansion into California with the launch of Diamond Infused Pre-Rolls. The rebrand of Grassroots coincides with the launch of its Grower's Reserve program, an ongoing series of limited-edition collaborations with craft farmers and diverse operators in California.
Tilt Holdings enters manufacture, distribution agreement with Curaleaf » 08:1711/0911/09/22
TILT Holdings announced…
TILT Holdings announced Jupiter Research has entered into an exclusive five-year manufacture, supply and distribution agreement with Curaleaf International to bring the Jupiter manufactured Liquid Que vaporizer to new territories abroad, for use as a medical device with extracts developed by Curaleaf International, subject to obtaining regulatory approvals in the relevant territories. Introduced in 2020, the Liquid Que vaporizer is the first independent pod system to be manufactured by Jupiter Research. Featuring a snap-in pod cartridge, magnetic connection, and rechargeable power supply, the Liquid Que's cutting-edge design preserves the integrity of high-viscosity extracts at every stage. Jupiter Research will be Curaleaf International's exclusive supplier of all vaporizer hardware, cartridges, and related accessories including the Liquid Que, for use with liquid medical cannabis products, bringing it initially to the United Kingdom and European Union, with other territories such as Switzerland, Norway, Australia, Israel, and the United Arab Emirates to follow. Curaleaf International will in turn develop each market, coordinate approval of the formulations and extracts in each territory per local regulations and distribute the approved Liquid Que device in these markets exclusively. The Liquid Que is expected to reach the UK beginning in late 2023.
Curaleaf price target lowered to C$8.50 from C$9.50 at Stifel » 11:5011/0811/08/22
Stifel analyst Andrew…
Stifel analyst Andrew Partheniou lowered the firm's price target on Curaleaf to C$8.50 from C$9.50 and keeps a Buy rating on the shares.
|Over a month ago|
Curaleaf reports Q3 EPS (7c), consensus (4c) » 16:0411/0711/07/22
Reports Q3 revenue…
Reports Q3 revenue $339.73M, consensus $337.99M.
Curaleaf assumed with a Buy at BTIG » 08:1510/2810/28/22
BTIG analyst Jonathan…
BTIG analyst Jonathan DeCourcey assumed coverage of Curaleaf with a Buy rating and C$10 price target. Curaleaf is the largest multi-state operator in U.S. cannabis and is "poised to benefit from that standing," DeCourcey tells investors in a research note. The analyst says Curaleaf has an established presence in every U.S. state market that does or will matter in the near term while recently having developed an early presence in potential large scale European markets "that could one day offer significant growth."
Cannabis stocks could rise about three times in near-term, says Stifel » 08:3310/0710/07/22
CRLBF, CURLF, GTBIF, TRSSF, TCNNF, ACB, CGC, CRON, TLRY
Stifel analyst Andrew…
Stifel analyst Andrew Partheniou notes yesterday's "surprise announcement" from President Biden of three executive actions surrounding cannabis pardons and initiating a review on cannabis scheduling, calling this "the most important development in US cannabis history since the Cole Memo." The most near term impact could be passing the SAFE Act, most likely through the NDAA in the lame duck session, and as a result he sees cannabis company shares "having the potential to increase up to 3x from current levels in short order." In the longer-term, dependent on scheduling outcomes, 280E could be addressed, which he sees having the potential to improve operating cash flows by 50%-250% for companies he covers in the space, Partheniou tells investors, adding "we could be on the cusp of a secular cannabis bull market." Stocks he covers that could be beneficiaries include Cresco Labs (CRLBF), Curaleaf (CURLF), Green Thumb Industries (GTBIF), TerrAscend (TRSSF) and Trulieve Cannabis (TCNNF). Other stocks in the space include Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON) and Tilray (TLRY).